Amicus Therapeutics, Inc. (FOLD) Raised to Strong-Buy at BidaskClub
Amicus Therapeutics, Inc. (NASDAQ:FOLD) was upgraded by BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued on Wednesday.
Several other research firms have also weighed in on FOLD. Robert W. Baird increased their price target on shares of Amicus Therapeutics from $12.00 to $15.00 and gave the company an “outperform” rating in a research report on Wednesday, July 12th. Zacks Investment Research lowered shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, July 12th. Cowen and Company restated a “buy” rating and set a $16.00 price target (up previously from $10.00) on shares of Amicus Therapeutics in a research report on Tuesday, July 11th. ValuEngine upgraded shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 9th. Finally, J P Morgan Chase & Co set a $13.00 price target on shares of Amicus Therapeutics and gave the company a “buy” rating in a research report on Monday, June 5th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $12.46.
Amicus Therapeutics (FOLD) traded down 0.59% during mid-day trading on Wednesday, hitting $13.53. 3,428,895 shares of the stock were exchanged. Amicus Therapeutics has a 52 week low of $4.41 and a 52 week high of $14.05. The stock’s 50-day moving average is $10.26 and its 200 day moving average is $7.65. The company’s market capitalization is $1.93 billion.
Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by $0.02. The company had revenue of $4.20 million for the quarter, compared to the consensus estimate of $4.16 million. Amicus Therapeutics’s revenue for the quarter was up 50.0% on a year-over-year basis. On average, analysts anticipate that Amicus Therapeutics will post ($1.44) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This news story was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/07/23/amicus-therapeutics-inc-fold-raised-to-strong-buy-at-bidaskclub.html.
In other Amicus Therapeutics news, major shareholder Life Sciences Maste Perceptive bought 1,500,000 shares of the business’s stock in a transaction on Thursday, July 13th. The stock was purchased at an average price of $12.25 per share, for a total transaction of $18,375,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Hung Do sold 29,914 shares of the stock in a transaction dated Friday, May 19th. The stock was sold at an average price of $8.00, for a total transaction of $239,312.00. Following the transaction, the insider now owns 474,438 shares of the company’s stock, valued at approximately $3,795,504. The disclosure for this sale can be found here. 3.40% of the stock is owned by company insiders.
Institutional investors have recently modified their holdings of the company. Principal Financial Group Inc. raised its position in shares of Amicus Therapeutics by 1.8% in the first quarter. Principal Financial Group Inc. now owns 26,883 shares of the biopharmaceutical company’s stock worth $192,000 after buying an additional 487 shares in the last quarter. KCG Holdings Inc. increased its stake in shares of Amicus Therapeutics by 1.1% in the first quarter. KCG Holdings Inc. now owns 66,066 shares of the biopharmaceutical company’s stock worth $471,000 after buying an additional 743 shares during the last quarter. Aperio Group LLC increased its stake in shares of Amicus Therapeutics by 13.5% in the second quarter. Aperio Group LLC now owns 13,986 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 1,663 shares during the last quarter. Metropolitan Life Insurance Co. NY increased its stake in shares of Amicus Therapeutics by 5.2% in the first quarter. Metropolitan Life Insurance Co. NY now owns 102,462 shares of the biopharmaceutical company’s stock worth $731,000 after buying an additional 5,041 shares during the last quarter. Finally, Creative Planning increased its stake in shares of Amicus Therapeutics by 56.2% in the first quarter. Creative Planning now owns 16,400 shares of the biopharmaceutical company’s stock worth $117,000 after buying an additional 5,900 shares during the last quarter.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.